Trial Profile
Erlotinib in non- or light-smoker patients with NSCLC harboring wild type EGFR and wild type ALK
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Feb 2015 Status changed from not yet recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 27 Feb 2014 New trial record